• Skip to main content
  • Skip to header right navigation
  • Skip to after header navigation
  • Skip to site footer
MyZA

MyZA

News, Directory, Events and Other Stuff

  • Social Media
  • Sport
  • World News
  • Home
  • Submit News
  • Directory
  • Events
  • Stratlec
  • TFSA
  • News
    • APO
    • Today’s Sport News
    • Todays Social Media and Tech Headlines
    • Today’s World News
    • Today’s SA Financial News
  • Contact
You are here: Home / News / SAHPRA warns of increased brain tumour risk with specific contraceptive use

SAHPRA warns of increased brain tumour risk with specific contraceptive use

17 January 2025 by Guest

SAHPRA warns of increased brain tumour risk with specific contraceptive use

The South African Health Products Regulatory Authority (SAHPRA) has advised that the product information for medroxyprogesterone acetate (MPA) be updated to include revised safety warnings, including the risk of meningioma.

MPA is a synthetic oral and injectable form of the hormone progesterone and is used for birth control and the management of endometriosis-associated pain. 

“It is also indicated in the palliative treatment of recurrent and/or metastatic endometrial cancer, renal cancer, and breast cancer in postmenopausal women,” the local watchdog explained. 

MPA-containing products registered in South Africa are Depo-Provera, Provera, Petogen, Medroxyprogesterone Mylan, Sayana, Omrastoz, Trivina, and Triclogyn. 

SAHPRA said it was informed by a holder of a Certificate of Registration (HCR) of regulatory action taken in Europe concerning products containing MPA, noting the potential risk of meningioma. 

“The regulatory action, which entailed updating product labelling, was based on the results of two epidemiological studies conducted in France and the United States which observed an increased risk of cerebral meningioma with prolonged use of MPA.”

Meningiomas 

Meningioma is a slow-growing tumour that develops in the meninges, the membranes that cover the brain and spinal cord.

The signs and symptoms of meningiomas vary depending on the tumour’s location. 

“Meningiomas are the only brain tumour more common among women than men. Meningiomas tend to occur in middle-aged and older adults.” 

The available evidence indicates that there may be an increased risk of developing meningioma in individuals taking MPA.

However, the occurrence of meningioma is expected to be very rare. 

According to global reports, there have been 32 cases identified over a 20-year period from 2004 to 2024. 

SAHPRA believes that the absolute risk of developing meningioma is low, especially considering the widespread use of MPA-containing products.

“Currently, no cases have been reported in South Africa. SAHPRA wishes to assure the public that the benefit-risk profile of registered MPA-containing medicines remains favourable. MPA is safe to use for its approved indications.” 

Meanwhile, the increased risk of meningioma was also detected with prolonged use of medrogestone and promegestone, which are progestogens that can be used to treat menstrual irregularities and breast cancer. 

However, SAPHRA said no medicines containing progestogens are marketed in South Africa at present.

Advice for healthcare professionals

Healthcare professionals have been encouraged to provide counselling to patients about the side effects of MPA detailed in the product information https://pi-pil-repository.sahpra.org.za/. 

It is also recommended that patients treated with MPA be monitored for signs and symptoms of meningioma under clinical practice. 

“If a meningioma is diagnosed in any patient treated with MPA for a non-oncological indication, the use of MPA must be stopped, as a precautionary measure.” 

Meanwhile, if a meningioma is diagnosed in any patient treated with MPA for an oncological indication, the need for further use of MPA should be carefully considered on a case-by-case basis, considering individual benefits and risks.

Advice for patients

Patients should talk to a healthcare professional before taking or continuing MPA. 

“It is important to use MPA for its approved indications and to follow the directions for use provided by healthcare professionals.”

Healthcare professionals and members of the public are urged to report any suspected adverse drug reactions (ADRs) related to the use of MPA and other health products to SAHPRA. 

This can be completed through the eReporting link on the SAHPRA website https://www.sahpra.org.za/e-services/ or by filling out an ADR reporting form available on the SAHPRA website and emailing it to adr@sahpa.org.za. 

Alternatively, reporting can be done via the Med Safety App, downloadable through Google Play or the Apple App Store. – SAnews.gov.za

Gabisile
Fri, 01/17/2025 – 13:51

261 views

The South African Health Products Regulatory Authority (SAHPRA) has advised that the product information for medroxyprogesterone acetate (MPA) be updated to include revised safety warnings, including the risk of meningioma.

MPA is a synthetic oral and injectable form of the hormone progesterone and is used for birth control and the management of endometriosis-associated pain. 

“It is also indicated in the palliative treatment of recurrent and/or metastatic endometrial cancer, renal cancer, and breast cancer in postmenopausal women,” the local watchdog explained. 

MPA-containing products registered in South Africa are Depo-Provera, Provera, Petogen, Medroxyprogesterone Mylan, Sayana, Omrastoz, Trivina, and Triclogyn. 

SAHPRA said it was informed by a holder of a Certificate of Registration (HCR) of regulatory action taken in Europe concerning products containing MPA, noting the potential risk of meningioma. 

“The regulatory action, which entailed updating product labelling, was based on the results of two epidemiological studies conducted in France and the United States which observed an increased risk of cerebral meningioma with prolonged use of MPA.”

Meningiomas 

Meningioma is a slow-growing tumour that develops in the meninges, the membranes that cover the brain and spinal cord.

The signs and symptoms of meningiomas vary depending on the tumour’s location. 

“Meningiomas are the only brain tumour more common among women than men. Meningiomas tend to occur in middle-aged and older adults.” 

The available evidence indicates that there may be an increased risk of developing meningioma in individuals taking MPA.

However, the occurrence of meningioma is expected to be very rare. 

According to global reports, there have been 32 cases identified over a 20-year period from 2004 to 2024. 

SAHPRA believes that the absolute risk of developing meningioma is low, especially considering the widespread use of MPA-containing products.

“Currently, no cases have been reported in South Africa. SAHPRA wishes to assure the public that the benefit-risk profile of registered MPA-containing medicines remains favourable. MPA is safe to use for its approved indications.” 

Meanwhile, the increased risk of meningioma was also detected with prolonged use of medrogestone and promegestone, which are progestogens that can be used to treat menstrual irregularities and breast cancer. 

However, SAPHRA said no medicines containing progestogens are marketed in South Africa at present.

Advice for healthcare professionals

Healthcare professionals have been encouraged to provide counselling to patients about the side effects of MPA detailed in the product information https://pi-pil-repository.sahpra.org.za/. 

It is also recommended that patients treated with MPA be monitored for signs and symptoms of meningioma under clinical practice. 

“If a meningioma is diagnosed in any patient treated with MPA for a non-oncological indication, the use of MPA must be stopped, as a precautionary measure.” 

Meanwhile, if a meningioma is diagnosed in any patient treated with MPA for an oncological indication, the need for further use of MPA should be carefully considered on a case-by-case basis, considering individual benefits and risks.

Advice for patients

Patients should talk to a healthcare professional before taking or continuing MPA. 

“It is important to use MPA for its approved indications and to follow the directions for use provided by healthcare professionals.”

Healthcare professionals and members of the public are urged to report any suspected adverse drug reactions (ADRs) related to the use of MPA and other health products to SAHPRA. 

This can be completed through the eReporting link on the SAHPRA website https://www.sahpra.org.za/e-services/ or by filling out an ADR reporting form available on the SAHPRA website and emailing it to adr@sahpa.org.za. 

Alternatively, reporting can be done via the Med Safety App, downloadable through Google Play or the Apple App Store. – SAnews.gov.za


Watch a SAHPRA warns of increased brain tumour risk with specific contraceptive use related video:

Stunning South Africa:

Have you visited MyPR?

MyPR.co.za offers free to publish press releases for your news site, blog or offline publication. Use the handy REPUBLISH facility or the Full Text RSS Feeds or just copy and paste.

Straton Electrical | Straton Solar | Straton Prepaid | Straton Plumbing | Straton IoT | Straton eBikes | BA Systems | Mbane Contracting | Reach Trust

Share this:

  • Share on X (Opens in new window) X
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Mastodon (Opens in new window) Mastodon
Category: NewsTag: 2024, Africa, African, App, Endometriosis, global, health, Healthcare, Registration, SA News, South Africa, United States, Video, Women

If you feel strongly about this article then feel free to send MyZA a ‘Letter to the Editor’ using the submission form below:


Letter to the Editor

This field is for validation purposes and should be left unchanged.
If this is in response to an article please include that article title here or as the lead in for the first paragraph of your Letter below.

Separate tags with commas

Localise your letter by naming the city your words are about. Add relevant words describing your subject. Single comma separated words of no more than 5
Your Name(Required)
Your Name will be linked to the website below.
Your personal, business or social media web site
Choose NO to not set up a user account on MyZA. User Accounts will allow you to submit letters under your own Author Name

3 Latest Letters to the Editor:

  • Older Persons Grants Land Today — No Need to Queue at Dawn

    Dear Editor, Older Persons grants are paid today, 30 October, under SASSA’s revised November payment schedule — with disability grants on Monday 2 November, children’s grants on Tuesday 3 November, and grants under review on Thursday 5 November. Two things every beneficiary should know. First, grant money does not expire on payment day. It stays…

    30 October 2026
  • November Grants Pay Early – No Need to Queue at Dawn

    Dear Editor, I run SAGrant (sagrant.co.za), a free resource helping South Africans navigate SASSA grants. November grants pay earlier than usual. Older Persons grants are paid on Friday 30 October, Disability grants on 2 November, and Child Support and other grants on 3 November. Grants still under review are paid on 5 November. The money…

    27 October 2026
  • NSFAS 2027 applications close on 31 October — SASSA households, apply now

    Dear Editor, I run SAGrant (sagrant.co.za), a free resource helping South Africans navigate SASSA grants. NSFAS applications for the 2027 academic year close on Friday 31 October 2026, and no extension is expected. If your household receives a SASSA grant, your child already passes the NSFAS financial eligibility test — but they still have to…

    25 October 2026

About Guest

Previous Post:Strides being made to reposition eThekwini
Next Post:The Perfect Towel for Kids at the Beach

Reader Interactions

Comments

  1. Nightmare King

    2 September 2026 at 6:37 am

    Did you knowthis about South Africa? South Africa celebrates its annual Heritage Day on 24 September. On this day, South Africans get together to celebrate their diverse cultures, traditions and beliefs. You’ll most likely find people enjoying a braai (barbecue) and dressed in traditional garb.

  2. Mad Jack

    26 August 2026 at 7:35 pm

    Van, startled, spins around and answers the rep, \”It\’s my donkey\’s ears. When they walk under the highway their ears rub along the roof and hurt them. I\’m making it taller so that doesn\’t happen\”.

    The rep looking confused, because it\’s a dirt track that runs under the bridge, asks him, \”Why don\’t you grade or dig some of the soil to lower the surface so they can pass through without their ears touching?\”

    Van – no the one looking confused then angry answers, \”No man, it\’s their ears that are too long, not their legs!\”

Copyright © 2026 · MyZA · All Rights Reserved · Powered by Stratlec Online